Mifepristone Manufacturers Rush Supreme Court to Block In-Person Abortion Pill Rule
Danco Laboratories, maker of the abortion pill mifepristone, filed an emergency appeal with the Supreme Court urging an immediate pause on a ruling by the 5th US Circuit Court of Appeals that reinstates strict in-person dispensing requirements for the medication.
The fast-track appeal, delivered late Saturday to conservative Justice Samuel Alito, warns that the lower court’s decision is causing “immediate confusion and upheaval” for patients seeking abortion access under time-sensitive medical windows. The 5th Circuit’s reinstatement of in-person pickup nationwide undermines access to medication abortion, which has surged since the court overturned Roe v. Wade.
“What should a patient do if she cannot obtain an in-person appointment immediately, or if she arrives at pharmacies across states like New York, Minnesota, and Washington today?” Danco’s attorneys ask in the appeal, highlighting the potential chaos for thousands relying on telehealth access established during the COVID-19 pandemic.
Why This Matters Now
Following the Supreme Court’s 2024 overturn of Roe, many conservative states banned or severely restricted clinic abortions. As a result, medication abortions accounted for more than 60% of all US abortions in 2026, according to the Guttmacher Institute. The Biden administration finalized rules last year allowing mifepristone to be prescribed via telehealth and mailed to patients without an in-person visit, broadening access nationwide.
The 5th Circuit’s ruling, which paused these federal regulations, was issued a day before Danco’s appeal. It revives a policy requiring the pill be handed out directly by certified providers at clinics or pharmacies — a step the company says will create “chaos” and disrupt already fragile abortion access, especially in states where clinic abortions are scarce.
Legal Battle Intensifies on Medication Access
The pharmaceutical maker requested the Supreme Court issue an “administrative stay” immediately to halt the 5th Circuit’s decision, allowing time for a full review of the case on its merits. This emergency petition thrusts mifepristone back on the high court’s docket just two years after the justices rejected a similar challenge, which kept the medication widely available.
Louisiana, one of multiple conservative states, has sued claiming the Biden-era policy conflicts with its abortion bans. A federal district court previously declined to restrict access to the pill until a federal safety review is complete. Yet, the ongoing legal dynamic places millions of patients at risk of losing crucial telehealth abortion access.
Public Health and Patient Impact
Data analysis by CNN, based on federal records, confirms the pill’s safety profile is strong — with fewer side effects reported than common medications like Viagra or penicillin. The swift adoption during the pandemic has proven vital for countless women who rely on remote medical care.
For Californians and others nationwide, this legal fight holds significant implications. With abortion laws varying dramatically state-by-state post-Roe, medication abortion remains one of the few accessible options for many. Any disruption to telehealth access to mifepristone may force travel, delays, or unsafe alternatives.
What’s Next
The Supreme Court’s response to Danco’s emergency appeal will be closely watched in the coming days. If the Court grants the stay, telehealth access to mifepristone continues uninterrupted for now. If not, millions face renewed barriers to medication abortion access immediately.
This case underscores the ongoing national battle over reproductive rights, placing medication abortion at the core of access debates amid a shifting legal landscape. The urgency and stakes this weekend could mark the next pivotal moment in abortion access across America.
